Cyclin E deregulation alters the biologic properties of ovarian cancer cells

被引:56
作者
Bedrosian, I
Lu, KH
Verschraegen, C
Keyomarsi, K
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
[4] Univ New Mexico, Canc Res & Treatment Ctr, Dept Expt Therapeut, Albuquerque, NM 87131 USA
关键词
ovarian cancer; cyclin E; cell cycle; lovastatin;
D O I
10.1038/sj.onc.1207408
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have previously shown that the low molecular weight (LMW) forms (trunk 1 and trunk 2) of cyclin E are biochemically hyperactive and induce G1/S progression in normal epithelial cells. Here we investigate the biologic consequences of LMW cyclin E expression in ovarian cancer cells. Using a panel of ovarian carcinoma tumors we find that cyclin E overexpression is invariably due to the presence of LMW forms and that expression of these forms appears to correlate with more advanced grade and stage of disease. Despite similar expression of p21 and p27, cyclin E overexpressing tumors have higher kinase function. Using an isogenic ovarian cancer model, we find that clones that overexpress the trunk 1 (T1) protein have a 10-fold increase in cyclin E kinase function, a 20% increase in S-phase fraction, a 10-15% decrease in doubling time and a 20% increase in colony formation compared to parental cells that express only the FL cyclin E protein. T1 clones were resistant to G1 arrest but more sensitive to cisplatin. Therefore, in ovarian tumors, the presence of LMW cyclin E forms confers altered biologic properties. Our data provides a potential mechanism for the poor prognosis of patients with LMW cyclin E expressing tumors.
引用
收藏
页码:2648 / 2657
页数:10
相关论文
共 35 条
  • [1] AKLI S, 2003, CANCER BIOL THER, V2, P16
  • [2] BUCKLEY MF, 1993, ONCOGENE, V8, P2127
  • [3] Cell cycle effects of gemcitabine
    Cappella, P
    Tomasoni, D
    Faretta, M
    Lupi, M
    Montalenti, F
    Viale, F
    Banzato, F
    D'Incalci, M
    Ubezio, P
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (03) : 401 - 408
  • [4] UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent
    Chen, XM
    Lowe, M
    Keyomarsi, K
    [J]. ONCOGENE, 1999, 18 (41) : 5691 - 5702
  • [5] Loss of cell cycle regulators p27Kip1 and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival
    Del Pizzo, JJ
    Borkowski, A
    Jacobs, SC
    Kyprianou, N
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (04) : 1129 - 1136
  • [6] Farley J, 2003, CANCER RES, V63, P1235
  • [7] Fukuse T, 2000, CANCER RES, V60, P242
  • [8] GrayBablin J, 1997, CANCER RES, V57, P604
  • [9] Harwell RM, 2000, CANCER RES, V60, P481
  • [10] Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary
    Itamochi, H
    Kigawa, J
    Akeshima, R
    Sato, S
    Kamazawa, S
    Takahashi, M
    Kanamori, Y
    Suzuki, M
    Ohwada, M
    Terakawa, N
    [J]. ONCOLOGY, 2002, 62 (04) : 349 - 353